The sample size for each group was relatively small (n=6-7), which may limit the statistical power and generalizability of the findings. Additionally, multiple cages were used for each treatment group, which could introduce variability and affect the results.
Lack of mechanistic insight
While the study measured several renal function parameters, it did not investigate the underlying molecular mechanisms by which resveratrol modulates the gut microbiota and protects against DN.
Potential confounding in FMT
The study used fecal samples from db/m mice as donors for FMT studies, which might confound the results due to potential residual resveratrol in the samples. Using FMT from resveratrol-treated db/db mice would provide a more direct assessment of the role of the altered gut microbiota.
Lack of functional analysis of gut microbiota
The study did not analyze the functional capacity of the gut microbiota, such as short-chain fatty acid production, which could be important in mediating the effects of resveratrol on DN.